Answers are grounded in this paper and cite their sources.
Survival analysis focused on the MET-E2F1-purine synthesis axis in clinical samples of TCGA cancer cohorts. Samples are differentiated by the under- and overexpression of individual transcripts. A, Impact of E2F1 and MET mRNA co-expression on survival of patients with lung, head and neck, stomach, and colorectal cancers. MET low/high percentiles 33/67. B, Impact of the mRNA co-expression of MET and GART/purine synthesis pathway-related enzymes on survival of patients with lung cancer. MET low/high percentiles 25/75. C, Impact of MET and RNR subunit (RRM1 and RRM2) mRNA co-expression on survival of patients with lung cancer. MET low/high percentiles 25/75.
No takes yet. Share an insight, caveat, or question.
Turan et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: